Roche’s aim to widen Evrysdi’s label nabs speedy FDA review in young spinal muscular atrophy patients
Now poised for a speedy trip through the FDA's regulatory review, Roche’s oral challenger in spinal muscular atrophy (SMA) could soon pick up a nod to cover all patie...
Continue Reading →
